NO20072155L - Clostridium-nevrotoksiner for anvendelse i vevheling - Google Patents

Clostridium-nevrotoksiner for anvendelse i vevheling

Info

Publication number
NO20072155L
NO20072155L NO20072155A NO20072155A NO20072155L NO 20072155 L NO20072155 L NO 20072155L NO 20072155 A NO20072155 A NO 20072155A NO 20072155 A NO20072155 A NO 20072155A NO 20072155 L NO20072155 L NO 20072155L
Authority
NO
Norway
Prior art keywords
neurotoxins
tissue
clostridium
local administration
clostridium neurotoxins
Prior art date
Application number
NO20072155A
Other languages
English (en)
Inventor
Harold Victor Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of NO20072155L publication Critical patent/NO20072155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Naturlig forekommende og/eller modifiserte Clostridium-nevrotoksiner, innbefattet slike nevrotoksiner frie for kompleksbindende proteiner som naturlig danner komplekser med Clostridium-nevrotoksiner, anvendes for å fremme heling av skadd overflatevev eller overflatisk vev hos en pasient ved lokal tilførsel i eller i nærheten av det skadde vev. Slike nevrotoksiner kan med fordel benyttes i sårheling og for å forhindre arrdannelse og kan anvendes innen området oftalmologi, f.eks. i behandling av skadd hornhinnevev, f.eks. ved lukking av betente øyne. En videre utførelse omfatter diagnostisk anvendelse for evaluering av effektiv toksintilførsel og medikamenter for anvendelse til dette.
NO20072155A 2004-09-27 2007-04-26 Clostridium-nevrotoksiner for anvendelse i vevheling NO20072155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61339204P 2004-09-27 2004-09-27
PCT/GB2005/003728 WO2006035225A1 (en) 2004-09-27 2005-09-27 Clostridial neurotoxins for use in tissue healing

Publications (1)

Publication Number Publication Date
NO20072155L true NO20072155L (no) 2007-04-26

Family

ID=35355850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072155A NO20072155L (no) 2004-09-27 2007-04-26 Clostridium-nevrotoksiner for anvendelse i vevheling

Country Status (13)

Country Link
US (1) US20060067950A1 (no)
EP (1) EP1799254A1 (no)
KR (1) KR20070057862A (no)
CN (1) CN101027083A (no)
AU (1) AU2005288758A1 (no)
BR (1) BRPI0516134A (no)
CA (1) CA2580122A1 (no)
EA (1) EA200700739A1 (no)
IL (1) IL182153A0 (no)
MX (1) MX2007003407A (no)
NO (1) NO20072155L (no)
WO (1) WO2006035225A1 (no)
ZA (1) ZA200702484B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US10076558B2 (en) 2014-02-18 2018-09-18 Rnw Skn, Llc Prophylactic normalization of cutaneous wound repair
CA3057302A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
AU2018237205A1 (en) * 2017-03-22 2019-10-31 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
CN107469065B (zh) * 2017-07-19 2021-05-18 广州医科大学 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
MXPA01004254A (es) * 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders

Also Published As

Publication number Publication date
WO2006035225A1 (en) 2006-04-06
ZA200702484B (en) 2008-11-26
BRPI0516134A (pt) 2008-08-26
CN101027083A (zh) 2007-08-29
EP1799254A1 (en) 2007-06-27
AU2005288758A1 (en) 2006-04-06
KR20070057862A (ko) 2007-06-07
MX2007003407A (es) 2007-05-23
EA200700739A1 (ru) 2007-10-26
US20060067950A1 (en) 2006-03-30
IL182153A0 (en) 2007-07-24
CA2580122A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
NO20072155L (no) Clostridium-nevrotoksiner for anvendelse i vevheling
Rabello et al. Update on hypertrophic scar treatment
ECSP077328A (es) Neurotoxinas clostridiales para uso en la cicatrización de tejidos
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
Verma et al. Office-based injection laryngoplasty for the management of unilateral vocal fold paralysis
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
CO6640331A2 (es) Tratamiento anti-envejecimiento de la piel
Hong et al. Impending skin necrosis after dermal filler injection: A “golden time” for first‐aid intervention
NZ710157A (en) Use of guanethidine for treating hypertension by local vascular delivery
WO2004000164A3 (en) Amniotic membrane mediated delivery of bioactive molecules
BRPI0513168A (pt) memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia
MX2011010781A (es) Una crema medicinal hecha con sulfadiazina de plata y quitosano y un proceso para hacerla.
Lee et al. Evaluation of a highly skin permeable low-molecular-weight protamine conjugated epidermal growth factor for novel burn wound healing therapy
MY190257A (en) Optimised subcutaneous therapeutic agents
van der Walt et al. Modified Charles procedure using negative pressure dressings for primary lymphedema: a functional assessment
JP2020511548A5 (no)
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
ATE444076T1 (de) Verwendung von botulintoxin zur linderung von hodenschmerzen
BR112014024358A2 (pt) uso de iduronate-2-sulfatase por via subcutânea e kit
HONG et al. Reactive vascular lesions treated using ethanolamine oleate sclerotherapy
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
Di Chiacchio et al. Ungual warts: comparison of treatment with intralesional bleomycin and electroporation in terms of efficacy and safety
BRPI0800085A2 (pt) composição farmacêutica e curativo para tratamento de lesões de pele, bem como uso de sal de cério associado a uma matriz de colágeno
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application